Our internationally recognised publications give you access to the expertise of hundreds of the world’s leading scientists, experts and researchers.

Our unrivalled collection of publications spans evidence-based clinical knowledge, research and regulatory information. The extensive breadth of content on MedicinesComplete supports your decision making, from research to the point of care and provides you with the world’s most trusted resources.

We’re excited to announce the launch of a new resource, Martindale’s ADR Checker, a quick and easy tool to support you when managing patients with adverse drug reactions.

Subscribe Publication Updates

Publication Updates

11 Dec
The Green Guide logo
Green Guide December 2018 update

Updates have been made to the following section of the Rules and Guidance for Pharmaceutical Distributors:

Chapter 5 – UK Guidance on Wholesale Distribution Practice

Subsection – ‘Short-term Storage of Ambient and Refrigerated Medicinal Products – Requirements for a Wholesale Dealer’s Licence’

11 Dec
Orange Guide logo
Orange Guide December 2018 update

Updates have been made to the following section of the Rules and Guidance for Pharmaceutical Manufacturers and Distributors:

Chapter 10 – UK Guidance on Wholesale Distribution Practice

Subsection – ‘Short-term Storage of Ambient and Refrigerated Medicinal Products – Requirements for a Wholesale Dealer’s Licence’

11 Dec
Handbook on Injectable Drugs logo
Handbook of Injectable Drugs December 2018 update

This update contains 5 new MedWatch alerts.

MedWatch Alerts Added: Fentanyl Citrate; Ketamine Hydrochloride; Neostigmine Methylsulfate; Norepinephrine Bitartrate; Succinylcholine Chloride

11 Dec
Stockley's Interactions Checker_logo
Stockley’s Interaction Checker December 2018 update 

New and updated interactions now available 

For December, 516 new interactions have been added, and 132 existing interactions have been updated

11 Dec
Clarke's Analysis of Drugs and Poisons logo
Clarke’s Analysis of Drugs and Poisons December 2018 update

Update contains 32 NPS monographs, 23 new additions and 9 full revisions, as well as minor updates.  

This update contains:

  • 8 new full NPS monographs
  • 9 fully revised NPS monographs
  • 15 new foundation NPS monographs
  • 59 Spectra
  • Updated prelims
  • Updated indices
11 Dec
Martindale logo
Martindale December 2018 update

This update contains 14 new monographs and 18 existing monographs have been updated. Preparations have been updated for 6 countries.

New monographs:

  • Angiotensin II and Angiotensin II Acetate: is a synthetic human angiotensin II that is used as a vasopressor in septic or other distributive shock.
  • Apalutamide: is a nonsteroidal anti-androgen that is used for the treatment of non-metastatic, castration-resistant prostate cancer.
  • Avatrombopag and Avatrombopag Maleate: is a thrombopoietin receptor agonist licensed to reduce bleeding risk in patients with chronic liver disease undergoing surgery.
  • Darvadstrocel: is an allogeneic expanded adipose-derived stem cell therapy. It is used for the treatment of fistulising Crohn’s disease.
  • Elagolix and Elagolix Sodium: is a gonadorelin antagonist. It is used for the management of moderate to severe pain associated with endometriosis.
  • Emicizumab: is a monoclonal antibody that acts as a factor VIII mimetic. It is used to prevent bleeding episodes in patients with haemophilia A who have developed factor VIII antibodies.
  • Eravacycline and Eravacycline Hydrochloride: is a tetracycline derivative that is used for the treatment of complicated intra-abdominal infections.
  • Latanoprostene bunod: is a synthetic analogue of dinoprost that is used topically in the treatment of glaucoma and ocular hypertension.
  • Padeliporfin and Padeliporfin Potassium: is a bacteriochlorophyll derivative that is used as a photosensitiser for the photodynamic therapy of prostate cancer.
  • Plazomicin and Plazomicin Sulfate: is a derivative of sisomicin that is used for the treatment of complicated urinary-tract infections, including pyelonephritis.
  • Sodium Zirconium Cyclosilicate: is a potassium binder that is used for the treatment of hyperkalaemia.
  • Tecovirimat: is an antiviral that inhibits the orthopoxvirus VP37 envelope wrapping protein that may be used for the treatment of smallpox in the event of an outbreak.
  • Tezacaftor: is a cystic fibrosis transmembrane conductance regulator (CFTR) protein corrector that is used in combination with ivacaftor in the treatment of cystic fibrosis.
  • Tildrakizumab: is a humanised monoclonal antibody that is an interleukin-23 antagonist and is used for the treatment of plaque psoriasis.

Notable revisions: 

  • Adalimumab: is used for the treatment of uveitis in children and hidradentis suppurativa in patients 12 years and older.
  • Ataluren: is used in children from the age of 2 years old for the treatment of Duchenne muscular dystrophy (DMD).
  • Certolizumab pegol: is used for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
  • Daclizumab: it has been withdrawn worldwide for the treatment of multiple sclerosis because of the risk of serious inflammatory brain disorders.
  • Fosaprepitant: is used in children from the age of 6 months old for nausea and vomiting associated with chemotherapy.
  • Mogamulizumab: is used for the treatment of mycosis fungoides, Sezary syndrome, and cutaneous and peripheral T-cell lymphoma.
  • Rufinamide: is used in children from 1 year of age in the treatment of Lennox-Gastaut syndrome.
  • Tapentadol: can be used in children from 2 years of age for the management of moderate to severe pain.
  • Tiotropium Bromide: is used in children from 6 years of age for the treatment of asthma.

Updated names, synonyms and codes; official standards; official preparations: 

  • USP41/USNF36.

Proprietary Preparations and Manufacturers updated for the following countries and regions: 

  • Belgium
  • Czech Republic
  • Ireland
  • Norway
  • UK
  • USA
View more